Industry news

02 October 2015

Range of refractive independence and mechanism of action of a corneal shape–changing hydrogel inlay: Results and theory

Roger F. Steinert, MD, Jim Schwiegerling, PhD, Alan Lang, PhD, Adam Roy, MS, Keith Holliday, PhD, Enrique Barragán Garza, MD, Arturo S. Chayet, MD / Journal of Cataract Refractive Surgery

The clinical data presented show the corneal inlay significantly improved near and intermediate uncorrected visual acuities across a 2.0 D range of preoperative refractive range (-0.5 D to +1.50 D) and age-related reading ADD powers between +1.50 D to +2.50 D.  Near task performance was also significantly improved in good and dim light compared to preoperative levels.  In the treated eye, the mean postoperative visual acuities were: 20/25 (near), 20/25 (intermediate), and 20/32 (distance).   The clinical outcomes are explained by the center-near power profile of the cornea induced by the shape-changing inlay providing zones within the pupil for good near, intermediate, and distance image quality.  And this thesis is confirmed by optical ray-trace predictions of visual acuity over this preoperative refractive range at distance, intermediate and near. 

Scientists create world’s largest catalog of human genomic variation

U.S. National Institute of Health

An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases. 

What Cures Are We Missing Out On?

John Tozzi / Bloomberg Business

MIT economist shows how powerful incentives block urgently needed research. Imagine a pill that eliminates the risk of cancer if you take it for 20 years. Such a breakthrough would become a blockbuster drug, making many billions in profit for the pharmaceutical company that discovered it, right?

ch.

Looking for the next wave of pharma innovation? Try opening the door to more partners, Accenture says

Beth Snyder Bulik / FiercePharmaMarketing

Welcome to the "We Economy," pharma. As all companies become digital, collaboration is the way things get done, with employees, customers, other industry players and new partners all pitching in to drive growth and innovation, according to Accenture's Technology Vision 2015 for Life Sciences study.

01 October 2015

Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today that results from a clinical trial of acebilustat in CF patients will be presented at the 29th North American Cystic Fibrosis Conference (NACFC) in Phoenix Oct 8-10, 2015.

Sean Parker's pleasantly nondisruptive take on immuno-oncology

Damian Garde / Fierce Biotech

Sean Parker is a very rich man. He has, according to Forbes, about $2.5 billion to his name, and he made most of it by investing in the likes of Napster, Facebook and Spotify, along the way deploying a great many Silicon Valley platitudes about "changing the world," "hacking" various things and, of course, "disrupting" most everything else.

Report: Women have fewer procedures after heart attack than men

Emily Wasserman / FierceMedicalDevices

Amid a growing body of research on heart health devices and blood pressure monitoring, a new report from Blue Cross Blue Shield shows that women undergo fewer diagnostic procedures and treatments following a heart attack than men.

New Study Reveals Immunotherapy More Effective Than Chemotherapy

Randi Hernandez / BioPharm International

Study results published in the New England Journal of Medicine comparing the efficacy of an immunotherapy with chemotherapy as a second-line treatment for nonsquamous non–small-cell lung cancer (NSCLC) signal a potential turning point in the therapeutic landscape of cancer. 

Moscow and federal funds invest in biosolutions for diagnostics and research

MarchMont Innovation News

The Moscow Seed Fund and the RVC Biofund, an investment arm of RVC, Russia’s fund of funds for innovation, have anted up $180,000 in Central Factory of Prepared Solutions (CFPS), a Russian company, the RVC website  announced . 
 

30 September 2015

Neothetics Initiates Study to Evaluate the Safety of LIPO-202 for Body Contouring in Obese Subjects

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the safety study, LIPO-202-CL-21, of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.